Hugel said Wednesday that it has completed phase 1 clinical trials on BMT101, a hypertrophic scar treatment developed initially by Olix Pharmaceutical. The company acquired exclusive sales right for the treatment in Asian countries in 2014.
Hypertrophic scarring refers to a condition where the wound from a surgery or trauma becomes abnormally hyperplastic, which in turn leaves a swollen scar around the wound.
The symptom has become prevalent over the years, with approximately 32 percent of all patients undergoing surgery developing hypertrophic scars within one year of the operation. Especially, Asia has a higher proportion of patients that portray symptoms compared to Westerners. Some studies have found that hypertrophic scarring occurs in about 37 percent of Caucasians, compared to 44.6 to 70 percent in Asians and non-white people.
Hugel plans to enter clinical phase 2 on BMT101 shortly and aims to commercialize it in 2021.
“The completion of BMT101 clinical phase 1 clinical trial is the result of strengthening the company’s R&D capacity for therapeutic markets and new drugs,” Hugel CEO Sohn Ji-hoon said. “The company plans to become a global biopharmaceutical company through continuous research and development.”
<© Korea Biomedical Review, All rights reserved.>